Clinical trial
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft…
NCT00157716 · Medicure, Industry · Completed
Key facts
| NCT number | NCT00157716 |
|---|---|
| Title | MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Cardiovascular and Cerebrovascular Effects of MC-1 in Patients Undergoing High-Risk Coronary Artery Bypass Graft (CABG) Surgery |
| Lead sponsor | Medicure, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization |
| Intervention type | Drug |
| Interventions | (MC-1) Pyridoxal-5'-phosphate |
| Enrollment | 900 |
| Start date | Apr 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Oct 31, 2006 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: